Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA) — Financial Flexibility Index

Latest as of September 2025: 0.02x

Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA) has a Financial Flexibility Index of 0.02x as of September 2025. Free cash flow of $137.91K (operating CF $137.91K minus capex $4.00) represents 0% of total liabilities ($7.36 Million). Explore Drugs Made In America Acquisition Corp. cash debt coverage ratio to assess how comfortably operating cash covers total debt obligations.

Financial Flexibility Index

0.02x
Free Cash Flow / Total Liabilities

Free Cash Flow

$137.91K
Operating CF − Capex

Total Liabilities

$7.36 Million
USD

Capital Expenditures

$4.00
USD

Drugs Made In America Acquisition Corp. Ordinary Shares Financial Flexibility Index (2024–2024)

Historical Financial Flexibility Index trend for Drugs Made In America Acquisition Corp. Ordinary Shares across 1 annual periods. See DMAA net asset quality index to measure how much of total assets are equity-financed.

Annual Financial Flexibility Index for Drugs Made In America Acquisition Corp. Ordinary Shares (2024–2024)

Year-by-year free cash flow to debt coverage for Drugs Made In America Acquisition Corp. Ordinary Shares. For the full company profile including market capitalisation, see DMAA company net worth.

Year Flexibility Index Free Cash Flow (USD) Operating CF Total Liabilities YoY Change
2024 -216.50x $-172.26K $-172.26K $795.67
Financial Flexibility Index = (Operating CF − Capex) / Total Liabilities = Free Cash Flow / Total Liabilities